Table 1.
Characteristicsa of the study population
| Overall (N = 215 744) | Men (n = 100 078) | Women (n = 115 666) | |
|---|---|---|---|
| Demography | |||
| Age, years | 56.70 (9.59) | 57.10 (9.75) | 56.35 (9.44) |
| Rural | 65 086 (30.34%) | 30 016 (30.15%) | 35 070 (30.51%) |
| Smokers (current or ever) | 57 961 (26.87%) | 53 861 (53.82%) | 4100 (3.54%) |
| Finished high school | 108 120 (50.11%) | 55 576 (55.53%) | 52 544 (45.43%) |
| Family history of ASCVD | 1318 (0.61%) | 701 (0.70%) | 617 (0.53%) |
| Blood pressure | |||
| SBP, mmHg | 134.45 (16.64) | 134.58 (16.37) | 134.32 (16.88) |
| DBP, mmHg | 82.63 (9.87) | 83.10 (9.90) | 82.18 (9.81) |
| Obesity | |||
| Waist circumference, cm | 81.76 (7.94) | 83.93 (7.61) | 79.90 (7.73) |
| BMI, kg/m2 | 23.31 (2.87) | 23.44 (2.71) | 23.21 (3.01) |
| Lipid metabolism | |||
| Total cholesterol, mmol/L | 4.90 (0.98) | 4.77 (0.97) | 5.01 (0.98) |
| HDL-C, mmol/L | 1.30 (0.34) | 1.25 (0.34) | 1.35 (0.33) |
| TG, mmol/L | 1.61 (1.09) | 1.66 (1.20) | 1.56 (0.99) |
| LDL-C, mmol/L | 2.84 (0.82) | 2.77 (0.81) | 2.90 (0.83) |
| Apo A, mmol/L | 1.22 (0.27) | 1.18 (0.27) | 1.26 (0.27) |
| Apo B, mmol/L | 0.95 (0.25) | 0.95 (0.25) | 0.95 (0.25) |
| Lp-(a), mmol/L | 4.87 (0.14) | 4.60 (0.14) | 5.12 (0.15) |
| Glucose metabolism | |||
| FBG, mmol/L | 5.67 (1.57) | 5.76 (1.72) | 5.60 (1.44) |
| HbA1c, % | 6.86 (1.90) | 6.99 (1.98) | 6.73 (1.82) |
| Diabetes mellitus | 26 090 (12.09%) | 12 364 (12.35%) | 13 726 (11.87%) |
| Renal function | |||
| eGFR, mL/min/1.73 m2 | 98.92 (15.30) | 97.71 (15.28) | 99.94 (15.25) |
| ACR, mg/g | 15.90 (45.36) | 16.32 (48.91) | 15.57 (42.39) |
| Medication | |||
| Anti-hypertension treatment | 75 857 (35.16%) | 35 590 (35.56%) | 40 267 (34.81%) |
| Anti-hyperlipidaemia treatment | 35 561 (16.48%) | 15 662 (15.65%) | 19 899 (17.20%) |
| Anti-hyperglycaemia treatment | 22 847 (10.59%) | 10 881 (10.87%) | 11 966 (10.35%) |
| Aspirin treatment | 19 064 (8.84%) | 9100 (9.09%) | 9964 (8.61%) |
| Outcome | |||
| ASCVD events | 6081 (2.82%) | 3272 (3.27%) | 2809 (2.43%) |
| Average follow-up time, years | 5.41 (1.36) | 5.41 (1.51) | 5.41 (1.22) |
| Incidence rate of ASCVD, per million person-years (95% CI) | 6178 (6177–6179) | 7242 (7241–7243) | 5245 (5244–5246) |
aCategorical variables are presented by counts and percentages; continuous variables are presented by means and SDs. All summarized statistics are given based on the complete sets of each predictor.